231 related articles for article (PubMed ID: 2857378)
1. Effects of cyclosporin on bullous pemphigoid and pemphigus.
Thivolet J; Barthelemy H; Rigot-Muller G; Bendelac A
Lancet; 1985 Feb; 1(8424):334-5. PubMed ID: 2857378
[No Abstract] [Full Text] [Related]
2. The treatment of pemphigus and pemphigoid.
Levene GM
Clin Exp Dermatol; 1982 Nov; 7(6):643-52. PubMed ID: 6758996
[No Abstract] [Full Text] [Related]
3. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid.
Tappeiner G; Steiner A
J Am Acad Dermatol; 1989 Apr; 20(4):684-5. PubMed ID: 2469705
[No Abstract] [Full Text] [Related]
4. [Are there indications for cyclosporin A in dermatology?].
Mensing H
Hautarzt; 1986 Aug; 37(8):421-3. PubMed ID: 3759450
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic experience in pemphigus and pemphigoid].
Aloi FG; Pippione M
G Ital Dermatol Venereol; 1984; 119(5):357-64. PubMed ID: 6392076
[No Abstract] [Full Text] [Related]
6. [Therapy of pemphigus and pemphigoid].
Schaumburg-Lever G
Z Hautkr; 1986 Jun; 61(11):811-2. PubMed ID: 3526731
[TBL] [Abstract][Full Text] [Related]
7. Blistering diseases in the mature patient.
Lakoš Jukić I; Jerković Gulin S; Marinović B
Clin Dermatol; 2018; 36(2):231-238. PubMed ID: 29566927
[TBL] [Abstract][Full Text] [Related]
8. [Autoimmune blistering skin diseases: diagnostic and therapeutic approach].
Hammers CM; Schmidt E; Zillikens D
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1473-7. PubMed ID: 24983196
[No Abstract] [Full Text] [Related]
9. Nutrition and bullous diseases.
Stoj V; Lu J
Clin Dermatol; 2022; 40(2):156-165. PubMed ID: 34808244
[TBL] [Abstract][Full Text] [Related]
10. The autoimmune bullous diseases.
Wakelin SH; Black MM
J R Coll Physicians Lond; 1997; 31(4):364-8. PubMed ID: 9263961
[No Abstract] [Full Text] [Related]
11. Autoimmune bullous dermatoses: a review.
Patrício P; Ferreira C; Gomes MM; Filipe P
Ann N Y Acad Sci; 2009 Sep; 1173():203-10. PubMed ID: 19758152
[TBL] [Abstract][Full Text] [Related]
12. Blistering skin disorders: an evidence-based update. Conference report.
Alexandroff AB; Harman KE
Br J Dermatol; 2009 Mar; 160(3):502-4. PubMed ID: 18945308
[TBL] [Abstract][Full Text] [Related]
13. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders.
Jolles S
Clin Exp Dermatol; 2001 Mar; 26(2):127-31. PubMed ID: 11298100
[TBL] [Abstract][Full Text] [Related]
14. New and emerging therapies in the treatment of blistering diseases.
Korman NJ
Dermatol Clin; 2000 Jan; 18(1):127-37, ix-x. PubMed ID: 10626118
[TBL] [Abstract][Full Text] [Related]
15. A survey of bullous diseases in a Turkish university hospital: clinicoepidemiological characteristics and follow-up.
Kutlubay Z; Sevim Keçici A; Çelik U; Mat MC
Turk J Med Sci; 2021 Feb; 51(1):124-133. PubMed ID: 32892539
[TBL] [Abstract][Full Text] [Related]
16. [Cyclosporin in the treatment of bullous pemphigoid: preliminary study].
Barthélémy H; Thivolet J; Cambazard F; Bendelac A; Mauduit G; Granier F; Frappaz A
Ann Dermatol Venereol; 1986; 113(4):309-13. PubMed ID: 3532906
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune blistering diseases: promising agents in clinical trials.
Olbrich H; Sadik CD; Schmidt E
Expert Opin Investig Drugs; 2023; 32(7):615-623. PubMed ID: 37526503
[TBL] [Abstract][Full Text] [Related]
18. [The hormonal profile of patients with pemphigus and bullous pemphigoid].
Klibson SK; Severovostokova VI; Shpanskaia LS
Vestn Dermatol Venerol; 1989; (7):37-41. PubMed ID: 2683471
[TBL] [Abstract][Full Text] [Related]
19. When and how to use sulfones in bullous diseases.
Jablonska S; Chorzelski T
Int J Dermatol; 1981 Mar; 20(2):103-5. PubMed ID: 7012048
[No Abstract] [Full Text] [Related]
20. Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.
Kim M; Borradori L; Murrell DF
Drugs Aging; 2016 Oct; 33(10):711-723. PubMed ID: 27738963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
